Digital Look

Welcome to Digital Look++,
you are not logged in

Advanced Search | Company A-Z | Feedback

Synairgen (SNG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

4.63p

Change Today:

0.040p
52 Week High: 9.80
52 Week Low: 3.40

Currency: UK Pounds
Shares Issued: 202.66m
Volume: 27,287

Market Cap: £9.38m
RiskGrade: 510
Beta: 1.47

Synairgen Overview

In the 1970s, Synairgen founder, British immunophysician Professor Sir Stephen Holgate, began investigating how respiratory viruses can cause serious illness, with the aim of translating these insights into effective clinical treatments. Joined by fellow University of Southampton professors Donna Davies and Ratko Djukanovic in the 1990s, together the three formed Synairgen in 2003 with the sole aim of bringing these advances to patients.

1 Day Chart

6 Month Chart

More Synairgen charts

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

	Latest	F'cast
Div Yield	0.0%	0.0%
Div Cover	n/a	n/a
Op Mrgn	n/a	n/a
ROCE	n/a

	Latest	F'cast
P/E	n/a	n/a
PEG	n/a	n/a
Pr/Revenue	n/a	n/a
Pr/Book	0.7

	Latest	F'cast
Revenue	n/a	n/a
PBT	n/a	n/a
EPS	n/a	n/a
DPS	n/a	n/a

Synairgen Fundamentals

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-19	n/a	(4.79)	(3.53)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-20	n/a	(17.73)	(9.46)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-21	n/a	(57.86)	(24.28)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	n/a	(20.09)	(8.76)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	n/a	(9.66)	(4.18)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Synairgen Forecasts

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-24	n/a	(7.00)	(2.98)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-25	n/a	(4.00)	(1.49)p	n/a	n/a	n/a	n/a	0.0%

Synairgen forecasts

Synairgen Company Announcements

Exercise of Share Options and Total Voting Rights	30-Oct-2024	18:09	RNS
Results of AGM and Appointment of New Chairman	10-Oct-2024	17:05	RNS
Interim Results	26-Sep-2024	07:00	RNS

More synairgen company announcements

Synairgen ShareCast News

Synairgen names Joseph Colliver as CFO	11-Oct-2023	ShareCast
Synairgen posts positive results for phase 2 tri...	04-Oct-2022	ShareCast
Synairgen unveils positive clinical trial data	07-Sep-2022	ShareCast

More Synairgen ShareCast news

Synairgen Top Newspaper Links

AstraZeneca buys the rights to an asthma treatme...	13-Jun-2014	Daily Mail
AstraZeneca in new £138million asthma drug deal	13-Jun-2014	Express & Star

Latest Synairgen Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Synairgen Market Data

Currency	UK Pounds
Share Price	4.63p
Change Today	0.040p
% Change	0.87 %
52 Week High	9.80
52 Week Low	3.40
Volume	27,287
Shares Issued	202.66m
Market Cap	£9.38m
Beta	1.47
RiskGrade	510